US Stock MarketDetailed Quotes
STXS Stereotaxis
- 1.910
- -0.130-6.37%
Close Oct 1 16:00 ET
- 1.940
- +0.030+1.57%
Post 20:01 ET
161.69MMarket Cap-7346P/E (TTM)
2.070High1.910Low243.08KVolume2.020Open2.040Pre Close470.84KTurnover0.42%Turnover RatioLossP/E (Static)84.66MShares3.29052wk High14.25P/B110.68MFloat Cap1.40052wk Low--Dividend TTM57.95MShs Float10.300Historical High--Div YieldTTM7.84%Amplitude1.330Historical Low1.936Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Stereotaxis Stock Forum
Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, has achieved significant milestones for its next-generation robotic system, GenesisX. The company has obtained CE mark in Europe and submitted a 510(k) application to the FDA in the US. GenesisX builds upon the established benefits of Robotic Magnetic Nav...
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment
Stereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory Framework
NEWS
First Heart Rhythm Patients in Southern Italy Treated with Advanced Robotic Technology
NEWS
Stereotaxis Reports 2024 First Quarter Financial Results
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, reported financial results for Q1 2024, ending March 31. Revenue grew 5% YoY to $6.9M, with system revenue at $2.6M and recurring revenue at $4.3M. Gross margin was 58%. Operating expenses were $8.7M, including $2.6M in non-cash stock compensation. Adjusted operating expenses were $6.1M, down from $6.9M YoY....
NEWS
Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced a definitive agreement to acquire Access Point Technologies EP (APT). APT, based in Minnesota, develops electrophysiology catheters used in cardiac ablation procedures. This acquisition enhances Stereotaxis' catheter development, manufacturing capabilities, and provides comme...
MBOT MVST AVRO HTCR MVLA KC STXS PACW
$Microbot Medical (MBOT.US)$ $Microvast (MVST.US)$ $Avrobio (AVRO.US)$ $HeartCore Enterprises (HTCR.US)$ $Movella Holdings (MVLA.US)$ $Kingsoft Cloud (KC.US)$ $Stereotaxis (STXS.US)$ $PacWest Bancorp (PACW.US)$
No comment yet